Prostamax vs Tadalafil
A side-by-side research comparison of Prostamax and Tadalafil across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Prostamax | Tadalafil |
|---|---|---|
| Full name | Prostamax (Prostate Peptide Bioregulator) | Tadalafil (Cialis) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound (peptide bioregulator) | FDA-approved prescription |
| Mechanism | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. | Selectively inhibits phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in smooth muscle. This enhances nitric oxide signaling for vasodilation in penile, pulmonary, and prostate tissue. |
| Molecular weight | ~ (short peptide) | 389.40 Da |
| Half-life | Short (peptide) | ~17.5 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~36% oral |
| Typical dose | ~1-2 capsules/day or short injectable courses | 2.5-5 mg daily or 10-20 mg as needed |
| Frequency | Once daily | Daily or on-demand |
| Route | Oral capsule or subcutaneous | Oral tablet |
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Tadalafil reported benefits
- Erectile function improvement
- Cardiovascular health (vasodilation)
- Prostate health (BPH)
- Improved exercise capacity
- Nitric oxide support
Related comparisons
Research and educational reference only. Not medical advice.